CYTOTRACK ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2016
2016/12
2017
2017/12
2018
2018/12
2019
2019/12
2020
2020/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  6.3% 16.0% 16.5% 11.6% 23.8%  
Credit score (0-100)  40 13 11 22 3  
Credit rating  BBB BB BB BB B  
Credit limit (kDKK)  0.0 -0.0 0.0 0.0 0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2016
2016/12
2017
2017/12
2018
2018/12
2019
2019/12
2020
2020/12

Net sales  0 0 0 0 0  
Gross profit  2,558 -224 -370 1,637 979  
EBITDA  211 -690 -461 251 -750  
EBIT  211 -690 -461 251 -750  
Pre-tax profit (PTP)  192.8 -709.9 -478.0 222.5 -789.2  
Net earnings  369.1 -709.9 -396.9 222.5 -789.2  
Pre-tax profit without non-rec. items  193 -710 -478 223 -789  

 
See the entire income statement

Balance sheet (kDKK) 
2016
2016/12
2017
2017/12
2018
2018/12
2019
2019/12
2020
2020/12

Tangible assets total  0.0 0.0 0.0 0.0 0.0  
Shareholders equity total  799 89.5 -307 -84.9 -874  
Interest-bearing liabilities  3,283 396 0.0 1.8 0.0  
Balance sheet total (assets)  4,269 485 5,943 3,713 4,154  

Net Debt  3,151 98.5 -5,819 -3,580 -4,026  
 
See the entire balance sheet

Volume 
2016
2016/12
2017
2017/12
2018
2018/12
2019
2019/12
2020
2020/12

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  2,558 -224 -370 1,637 979  
Gross profit growth  0.0% 0.0% -65.2% 0.0% -40.2%  
Employees  0 0 0 3 3  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  4,269 485 5,943 3,713 4,154  
Balance sheet change%  0.0% -88.6% 1,124.8% -37.5% 11.9%  
Added value  211.3 -690.4 -461.3 251.3 -749.8  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 0 0 0 0  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  1.0 -1.0 -2.0 1.0 -1.0  

Profitability 
2016
2016/12
2017
2017/12
2018
2018/12
2019
2019/12
2020
2020/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  8.3% 308.1% 124.6% 15.3% -76.6%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  4.9% -29.0% -13.7% 5.0% -17.0%  
ROI %  5.2% -30.2% -190.1% 27,778.0% -82,119.5%  
ROE %  46.2% -159.7% -13.2% 4.6% -20.1%  

Solidity 
2016
2016/12
2017
2017/12
2018
2018/12
2019
2019/12
2020
2020/12
Equity ratio %  18.7% 18.4% -4.9% -2.2% -17.4%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  1,491.4% -14.3% 1,261.3% -1,424.5% 537.0%  
Gearing %  410.7% 442.2% 0.0% -2.2% 0.0%  
Net interest  0 0 0 0 0  
Financing costs %  1.1% 1.1% 8.4% 3,403.1% 4,318.3%  

Liquidity 
2016
2016/12
2017
2017/12
2018
2018/12
2019
2019/12
2020
2020/12
Quick Ratio  1.2 1.2 1.0 1.0 0.8  
Current Ratio  1.2 1.2 1.0 1.0 0.8  
Cash and cash equivalent  131.7 297.2 5,818.8 3,581.5 4,026.2  

Capital use efficiency 
2016
2016/12
2017
2017/12
2018
2018/12
2019
2019/12
2020
2020/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  799.4 89.5 -307.4 -84.9 -874.1  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2016
2016/12
2017
2017/12
2018
2018/12
2019
2019/12
2020
2020/12
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 0 84 -250  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 84 -250  
EBIT / employee  0 0 0 84 -250  
Net earnings / employee  0 0 0 74 -263